Vivoryon Receives IND Approval for Varoglutamstat‘s (PQ912) Phase 2 Study in Alzheimer’s Disease
Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update
Vivoryon Receives IND Approval for Varoglutamstat‘s (PQ912) Phase 2 Study in Alzheimer’s Disease
Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update
HALLE (SAALE) / MUNICH, Germany, 20 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Half Year Results for 2020 on Thursday, August 27, 2020. The company will host a conference call and webcast (in English) open to the public. The Half Year Results 2020 will be available to download on the company website (www.vivoryon.com/investors-news/financial-information/).
Conference call details
Date: Thursday, August 27, 2020
Time: 3:00 pm CEST /09:00 am EDT
Access Code: 8118230#
From Germany: +49 (0)69 2222 2018
From UK: +44 (0)330 336 9411
From USA: +1 929 477 0448
Webcast details
A live webcast and accompanying slides will be made available at: www.vivoryon.com/investors-news/financial-information/
###
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com
Trophic Communication
Gretchen Schweitzer, Joanne Tudorica
Tel.: +49 172 861 8540 / +49 176 2103 7191
Email: vivoryon@trophic.eu
Notes to Editors:
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer’s disease and its entire portfolio of QC and QPCTL inhibitors in oncology and other indications. In addition, the Company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.